BioSpace

BioNTech faces 3rd mRNA setback as head and neck cancer therapy fails to improve survival

While BNT113 failed to improve progression-free survival in patients with a type of head and neck cancer during a Phase 3 trial, BioNTech is holding out hope for an overall survival win—but analysts say that outcome is now "less likely."

By BioSpace

1 min read
BioNTech faces 3rd mRNA setback as head and neck cancer therapy fails to improve survival
AI-generated illustration

Got news to share with the events industry?

Submit a press release or story tip and reach thousands of event professionals.

Get in touch→

More in Health Tech

Related Insights